-- Days : -- HRS : -- MIN : -- SEC

Register Now →

NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Opinion|Videos|March 13, 2025

An Introduction to NPC

Author(s)Lori J. Wirth, MD

A panelist discusses how nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies through its distinct geographical distribution, Epstein-Barr virus association, unique genetic profile, and characteristic clinical presentation, including early lymph node involvement.

Episodes in this series

1 expert is featured in this series.

EP. 1 An Introduction to NPC

1 expert is featured in this series.

EP. 2 A 48-Year-Old Man With Recurrent NPC

1 expert is featured in this series.

EP. 3 Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripalimab in the Recurrent Setting

1 expert is featured in this series.

EP. 4 Treatment Paradigms in R/M NPC: The Role of Systemic Immunotherapy

1 expert is featured in this series.

EP. 5 Clinical Perspectives for the Treatment of R/M NPC

Video content above is prompted by the following:

Provide a brief introduction to NPC.
Briefly discuss its incidence, molecular/genetic characteristics, and clinical hallmarks.
How does NPC differ from other types of head and neck cancers?

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

Experts featured in this series.

Multidisciplinary Supportive Care and Unmet Needs in ROS1-Positive Advanced Non-Small Cell Lung Cancer

ByEric Singhi, MD,Bruna Pellini, MD,Estelamari Rodriguez, MD, MPH,Gregory Riedlinger, MD, PhD,Idalmis Hernandez. NP

July 9th 2026

Experts featured in this series.

Second-Line Sequencing After Earlier-Generation ROS1 TKIs and the Role of Chemotherapy and Immunotherapy in ROS1-Positive Advanced Non-Small Cell Lung Cancer

ByEric Singhi, MD,Bruna Pellini, MD,Estelamari Rodriguez, MD, MPH,Gregory Riedlinger, MD, PhD,Idalmis Hernandez. NP

July 9th 2026

Experts featured in this series.

Multidisciplinary Management and CNS Surveillance in ROS1-Positive Advanced Non-Small Cell Lung Cancer

ByEric Singhi, MD,Bruna Pellini, MD,Estelamari Rodriguez, MD, MPH,Gregory Riedlinger, MD, PhD,Idalmis Hernandez. NP

July 9th 2026

Experts featured in this series.

Clinical Case 2 Continued: Second-Line Therapy Selection and CNS Management in ROS1-Positive Advanced Non-Small Cell Lung Cancer After Solvent-Front Resistance

ByEric Singhi, MD,Bruna Pellini, MD,Estelamari Rodriguez, MD, MPH,Gregory Riedlinger, MD, PhD,Idalmis Hernandez. NP

July 9th 2026

Experts featured in this series.

Clinical Case 2: ROS1-Positive Advanced Non-Small Cell Lung Cancer with Progression on First-Line Therapy and Solvent-Front Resistance

ByEric Singhi, MD,Bruna Pellini, MD,Estelamari Rodriguez, MD, MPH,Gregory Riedlinger, MD, PhD,Idalmis Hernandez. NP

July 9th 2026

Latest CME

25th Annual International Congress on the Future of Breast Cancer® West

In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® West

July 17-18, 2026

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

2 Sessions are Available!

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

1 Session is Available!

Rhode Island Oncology Society

Rhode Island Oncology Society

2 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Empire State Hematology & Oncology Society (New York)

Empire State Hematology & Oncology Society (New York)

2 Sessions are Available!

Minnesota Society of Clinical Oncology

Minnesota Society of Clinical Oncology

2 Sessions are Available!

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

1 Session is Available!

Washington State Medical Oncology Society

Washington State Medical Oncology Society

1 Session is Available!

Colorado Oncology Society

Colorado Oncology Society

1 Session is Available!

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

2 Sessions are Available!

Nevada Oncology Society

Nevada Oncology Society

2 Sessions are Available!

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Advanced Renal Cell Carcinoma: Selecting Between IO/TKI and IO/IO Combination Therapy

After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC

Unique Benefits Seen With CAR T in AL Amyloidosis

CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma

Recurrence Score Elevated in Breast Cancers Diagnosed Within 3 Years Postpartum